GlassScriptPhysician profile
Joshua Harris
NPI 1649531815
$6,486.74
in general payments reported to CMS, 2019-2025
21 companies · $2,232 in 2025
The $2,232 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20.00 · 2021: $600 · 2022: $1,003 · 2023: $871 · 2024: $1,761 · 2025: $2,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,238 · Food and Beverage: $1,626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,238.00 |
| Food and Beverage | $1,626.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,558.89 | 2022-2024 | |
| Janssen Biotech, INC. | $1,010.00 | 2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $890.00 | 2025 | |
| Abbott Laboratories | $525.95 | 2021-2022 | |
| Surmodics, INC. | $435.00 | 2023 | Pounce Thrombectomy, Pounce Venous Thrombectomy System, Pounce Thrombectomy System |
| Kerecis Limited | $330.10 | 2022-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Biom'Up France Sas | $313.36 | 2021 | |
| Progenics Pharmaceuticals, INC. | $258.53 | 2022-2023 | Pylarify |
| Pfizer INC. | $236.86 | 2024-2025 | |
| W. L. Gore & Associates, INC. | $183.94 | 2024 | Gore Tag Thoracic Branch Endoprosthesis |
| Integra Lifesciences Corporation | $160.98 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Shockwave Medical, INC | $158.10 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2025 | |
| Penumbra, INC. | $101.56 | 2022 | |
| Medtronic, INC. | $47.37 | 2025 | Protege Gps, Nitrex |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $43.78 | 2021 | |
| Janssen Pharmaceuticals, INC | $31.71 | 2021-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $22.38 | 2021 | |
| Seagen INC. | $20.00 | 2020 | |
| Genentech USA, INC. | $19.41 | 2021 | |
| Menarini Silicon Biosystems, INC. | $13.82 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.